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ABSTRACT 
Introduction: We wished to see the effects of inhaled PGE1 on diastolic dysfunction, left ventricular end diastolic 
pressure (LVEDP), pulmonary hypertension and hypoxia in ARDS patients. Methods: This is a randomized, prospec- 
tive, clinical trial conducted in the main adult intensive care unit of a tertiary care University hospital. A total of 67 pa- 
tients were recruited. Inclusion criteria included all adult patients with a P/F ratio <200 and/or Pulmonary Artery sys- 
tolic (Pa) pressures of >35 mmHg on Pulmonary artery catheter or suspected on clinical grounds. A transthoracic echo 
was performed to record the diastolic function, LVEDP and Pa pressures. Subsequently patients were randomized by a 
block computerized randomization to either cases (n = 34) or controls (n = 33). Cases received nebulised PGE1 over 30 
minutes in the ICU and normal saline was administered to controls blindly. Following this the echo and arterial blood 
gases were repeated. Our primary outcomes were an improvement in diastolic function and P/F ratio of greater than 
20% and a decrease in pulmonary pressure and LVEDP of >20%. Results: At baseline, mean diastolic dysfunction was 
grade II, with a mean LVEDP of >15 and the PaO2/FiO2 ratio was 148.38 ± 60.05 with a mean pulmonary artery pres- 
sure of 81.35 ± 16.91. Inhaled PGE1 was followed by an improvement in diastolic dysfunction (grade I, p = 0.001) with 
a resulting improvement in LVEDP (12 +/− 2, p = 0.001) as well as Pa pressures (97.09 ± 30.06, p = 0.04) and a non 
significant improvement in PaO2/FiO2 ratio (161.45 ± 77.52, p = 0.21). There were no side effects observed in any pa- 
tients. Conclusion: Our study shows that there is a significant improvement in diastolic dysfunction, LVEDP and Pa 
pressures after administration of nebulised PGE1, and an improvement although non-significant in hypoxia in ARDS 
patients. The trial was registered with Clinicaltrials.gov (NCT00314548) and funded by the Pakistan medical research 
council. 
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1. Introduction 
Adult Respiratory Distress Syndrome (ARDS) is charac- 
terized by hypoxemia, low lung compliance, pulmonary 
hypertension and diffuse radiological infiltrates due to in- 
creased microvascular permeability [1]. Clinically it is 
characterized by severe hypoxia with a PaO2/FiO2 ratio 
<200, Pa pressures >35 mmHg and possible diastolic dys- 
function, reportedly in 25% patients. The intravenous ap- 
plication of prostacyclin or its stable analogue, PGE1 
(alprostadil) has been used to cause a decrease not only 
of the pulmonary but also of the systemic vascular tone. 
Aerosolized PGE1 can result in a selective pulmonary 
vasodilatation without affecting the systemic blood pres- 
sure as shown in preliminary studies/case reports [2]. No 
large prospective trials exist for this type of use of the 
drug so far. Furthermore, aerosolized PGE1 can improve 
gas exchange and pulmonary shunt in clinical settings of 
impaired ventilation/perfusion ratio as occurs in Adult 
Respiratory Distress Syndrome (ARDS), due to the re-  
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distribution of pulmonary blood flow from non-venti- 
lated to ventilated, aerosol accessible lung regions [3,4]. 
Pulmonary hypertension, defined as mean pulmonary ar- 
tery (Pa) pressure of >25 mmHg, is an end point of a va- 
riety of conditions. These include primary pulmonary hy- 
pertension, post-operative pulmonary hypertension and 
as a result of increased pulmonary vascular resistance that 
occurs in ARDS [5-7].  
Previous case reports and non randomized studies have 
indicated that inhalation of aerosolized alprostadil (an 
analog of prostacyclin) may offer a new life saving stra- 
tegy in intractable pulmonary hypertension and ARDS 
[8-10]. Further advantages of inhaled alprostadil are the 
lack of adverse reactions and toxic side effects; as well as, 
convenient and more cost effective administration. Other 
available therapies like Nitric Oxide inhalation are ex- 
pensive and are also associated with additional side effects, 
such as thrombocytopenia. Alprostadil is completely meta- 
bolized and excretion of metabolites is primarily via the 
kidneys; the elimination half life is 30 minutes. Inha- 
lation therapy reduces systemic absorption and hence 
time for elimination [11]. There is an absence of RCTs 
and systematic reviews on this particular use of the drug 
for the given specific objectives in literature. The clinical 
rationale for this study was the untreatable nature of 
ARDS associated with a high mortality (>30%) and the 
incidence of ARDS being >10% in our ICU (ICU Qua- 
lity Indicators Janaury-April 2005-6 [12]). Ours was a trial 
to show that nebulized PGE1 improves diastolic dysfunc- 
tion and LVEDP as well as decreases pulmonary hyper- 
tension selectively and improves oxygenation in ARDS. 
Even though the effect of this treatment may be too short 
lived for a pathophysiological process spanning weeks, 
we wished to try and find a positive effect of the drug to 
minimize the associated complications.  
2. Materials and Methods 
This was a single center, prospective, double blind, place- 
bo-controlled, parallel-group study with a balanced ran- 
domization conducted in Pakistan. Written approval of 
Aga Khan University Ethics Review Committee was ob- 
tained prior to commencement of the study. Eligible par- 
ticipants were all adults aged 18 or over with ARDS who 
met the inclusion criteria. 
Setting: The study took place in an adult, multi-disci- 
plinary, “open-policy”, 11 bedded Intensive Care Unit in 
a tertiary care hospital of Karachi, Pakistan from May 
2006 to February 2008  
Patients: A total of 67 patients were enrolled after ob- 
taining informed consent in the patient’s native language. 
Inclusion criteria: After screening all admissions on a daily 
basis by a Research officer patients were included if they 
fulfilled the following ARDS criteria: 1) a PaO2/FiO2 < 
200 arterial hypoxemia, bilateral infiltrates on chest X- 
ray and a wedge pressure of <18 mmHg on Swan Ganz 
parameters if present or if no signs of congestive heart 
failure were present on echo 2) all patients admitted to 
the ICU with pulmonary hypertension (Pa systolic pres- 
sure of >35 mmHg) or 3) all patients in the ICU with 
post operative pulmonary HTN. Exclusion criteria: Pa- 
tients were excluded if they had a diagnosis of 1) pul- 
monary embolus; 2) cor pulmonale; 3) an ejection frac- 
tion of <30% or a pulmonary artery wedge pressure of > 
18 mmHg; 4) nonintubated patients; and 5) paediatric pa- 
tients (<18 years of age). Controls were chosen from se- 
lected patients included in the study in a random, blinded 
manner. Patients were given either a drug or placebo bas- 
ed on the following blinding procedure. After enrolling, 
the following tests were carried out 1) a trans-thoracic 
echo to establish pulmonary hypertension and rule out an 
ejection fraction <30% and presence of a pulmonary em- 
bolus and 2) routine arterial blood gas and CXR were 
reviewed to determine ARDS criteria. Transthoracic echo 
helped determine the left ventricular end diastolic pres- 
sures (LVEDP) and diastolic dysfunction. The echocar- 
diographic doppler grades of diastolic function based on 
mitral inflow patterns are impaired relaxation (grade I) 
which results from impairments in active relaxation but 
is not associated with a change in mean left atrial pres- 
sure. Further grades of diastolic dysfunction by echocar- 
diographic doppler are grades II [pseudonormal] and III 
[restrictive] which are associated with an increased mean 
left atrial pressure [13]. Left ventricular end diastolic 
pressures (LVEDP) of <10 mmHg were considered nor- 
mal, 10 - 15 mmHg were intermediate and >15 mmHg 
were considered as increased. 
2.1. Interventions 
Patients were randomly assigned to receive PGE1 or 
normal saline in a concealed syringe which the bedside 
nurse dispensed as a nebulizer in 5 ml of saline over 30 
minutes. The drug alpostadil was nebulized continuously 
at 20 micrograms in normal saline over 30 minutes [8,13]. 
Drug administration was carried out within one hour of 
the first transthoracic echo and arterial blood gases. Pa- 
tients in the control and intervention groups received 
usual care at the discretion of their intensivist. All cost of 
investigations and drug were borne by the grant obtained 
for this study prior to commencement. Baseline PaO2/ 
FiO2 ratio was obtained from the arterial blood gas ana- 
lysis (ABG) documented in the flowsheet which is rou- 
tinely carried out in the ICU on all ventilated patients. 
Baseline diastolic function, left ventricular end diastolic 
pressure and Pa pressure was obtained on echocardio- 
gram in all patients. After the enrolment with a PaO2/ 
FiO2 ratio less than 200 and a Pa pressure greater than 35 
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mm Hg, PGE1 or placebo was nebulised in 5 cc of nor- 
mal saline for thirty minutes by the bedside nurse using 5 
L of oxygen. Jet nebulizers were used connected by tub- 
ing to a compressor, that usually causes compressed air 
or oxygen to flow at high velocity through a liquid medi- 
cine to turn it into an aerosol, which is then inhaled by 
the patient. During this time the haemodynamics and sa- 
turation was closely monitored and the patient was ex- 
cluded if there was instability or if hypoxia worsened. A 
repeat ABG and echocardiogram was performed at the 
bedside after one hour of drug administration to record 
the “after drug” parameters. 
2.2. Standardization of Care 
Standardization of treatment modalities have been in- 
corporated in our methodology with regard to ventilatory 
support, inotropic support and fluid management. A gen- 
eral range of parameters for ARDS and end goal directed 
therapy of the Surviving Sepsis campaign were main- 
tained, keeping in mind the recommendations of the So- 
ciety of Critical Care medicine and the Acute Respiratory 
Distress Syndrome Network [14-16]. Once enrolled, the 
patients were managed by the ICU Consultant in consul- 
tation with the primary physician along the following 
lines: any ventilatory mode could be used as long as peak 
airway pressures (PAw) were maintained under 35 
mmHg. Peep range was between 8 - 14 mmH and tidal vo- 
lumes of 6 cc/kg were used. Inotropic support, if needed, 
was maintained by using intravenous infusion of Dopa- 
mine (5 - 20 mics/kg/min, a positive inotrope (dopami- 
nergic, alpha and beta agonist activity) and norepineph- 
rine (0.1 - 0.5 mics/kg/min) a vasopressor (alpha agonist) 
to maintain a mean arterial pressure of >60 mmHg. CVP 
pressures of 8 - 12 cm H2O and an adequate urine output 
of >0.5 cc/kg/hr were the goal of fluid management. 
2.3. Outcome Measures 
The primary end point with respect to efficacy of inhaled 
PGE1 in ARDS was the proportion of patients achieving 
a 25% improvement in diastolic dysfunction, LVEDP, Pa 
pressures and PaO2/FiO2 ratio from baseline as measured 
by a repeat transthoracic echo and arterial blood gas ana- 
lysis thirty minutes after the drug was administered. 
2.4. Randomisation and Allocation Concealment 
Independent pharmacists dispensed either active or pla- 
cebo drug according to a computer generated randomiza- 
tion list. The PGE1 and placebo were dispensed from 
pharmacy in a syringe form concealed with an alumin- 
ium foil. They were consecutively numbered for each pa- 
tient according to the randomization schedule.  
2.5. Blinding and Data Collection 
Each patient after enrolment was assigned a serial num- 
ber consecutively after meeting the inclusion criteria re- 
viewed by the principal investigator and research assis- 
tant. After the necessary workup and consent, drug was 
obtained from the AKUH Pharmacy. All investigators, 
staff and patients were kept masked to outcome meas- 
urements and allocation. Data was collected by the re- 
search assistant on a data collection form. At the end of 
trial the serial numbers of the patients were matched to 
the delivery chart of the pharmacy to see whether they 
obtained PGE1 or placebo. Variables recorded are given 
in Table 1. 
2.6. Statistical Methods 
Epi-info version 1.1 was used to calculate sample size. 
Assuming a total population of over 15 million (2010 
Demographic Survey of Pakistan) of all age groups, and 
taking the incidence of 20% (± 105 bound of error) of 
Pulmonary hypertension and ARDS at 95% confidence 
interval, we extricated a sample size to be 60 cases, to 
achieve a power of 80% and a significance of 5% (α = 
0.05) [17]. We predicted a 10% attrition rate. The pri- 
mary end point was change in diastolic dysfunction, 
LVEDP, Pa pressures and PaO2/FiO2 ratio during the 
study in the intention-to-treat principle. Descriptive sta- 
tistics were performed. An independent samples Stu- 
dent’s t-test was used to test for significant differences at 
baseline before drug and between groups after drug. 
Group means of cases and controls were then calculated 
and compared using a repeated measures analysis of va- 
riance (ANOVA) procedure. 
3. Results 
Two hundered consecutive patients were screened be- 
tween May 2006 and Feb 2008. Twenty patients refused 
to enroll. Seventy two patients were enrolled after meet- 
ing the inclusion criteria and after informed consent was 
obtained from the next of kin as well as permission ob- 
tained from the primary physician. Five patients were 
excluded later as they expired before drug administration. 
Finally, 34 were randomized to the PGE1 group and 33 
to the placebo group. The characteristics of the final 67 
patients are summarized in Table 1, including the age, 
gender, baseline diastolic dysfunction, LVEDP, Pa pres- 
sure and PaO2/FiO2 ratio. At baseline, mean diastolic 
dysfunction was grade II, with a mean LVEDP of >15 
and the PaO2/FiO2 ratio was 148.38 ± 60.05 with a mean 
pulmonary artery pressure of 81.35 ± 16.91. Patients were 
well matched for age, type of admission, illness severity, 
and other clinical characte istics. Figure 1 illustrates r    
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Table 1. Comparison between the two groups pre-intervention at baseline (Data are means % and 95% CI). 
 PGE1 group (n = 34) Placebo group ( n = 33) p value 
Age (years) 48.22 (41.63 - 54.81) 48.21 (42.55 - 53.87) 0.056 
APACHE II score 24 (22.82 - 25.18) 21 (19.23 - 22.70)  
Males (%) 62.5 (45.12 - 77.09) 71.9 (54.47 - 84.40) 0.42 
Females (%) 37.5 (22.90 - 54.87) 28.1 (15.59 - 45.52)  
Diastolic dysfunction    
Nl 0 3.0 (0.72 - 15.32) 0.10 
I 14.7 (6.56 - 30.25) 15.2 (6.76 - 31.05)  
IA 58.8 (42.11 - 73.67) 48.5 (32.42 - 64.87)  
II 2.9 (0.69 - 14.91) 21.2 (10.74 - 37.89)  
LVEDP (mmHg)    
<10 3.8 (0.91 - 18.97) 3.4 (0.08 - 17.21) 0.97 
10 - 15 19.2 (8.62 - 38.08) 17.2 (7.71 - 34.72)  
>15 76.9 (57.74 - 88.88) 79.3 (61.43 - 90.06)  
PaO2/FiO2 baseline 141.15 (120.77 - 161.53) 163.41 (140.84 - 185.98) 0.17 
Pa pressure baseline (mmHg) 81.99 (76.5 - 87.48) 80.40 (71.25 - 89.55) 0.77 
 
the trial profile.  
 
The primary analysis was intention-to-treat and in- 
volved all patients who were randomly. Group means of 
cases and controls were calculated and compared using a 
repeated measures analysis of variance (ANOVA) model 
which that, when separately considered, there was a sig- 
nificant difference in Pa pressures after the drug admini- 
stration between the cases and controls (p = 0.04). There 
was a marginal non significant difference in the PaO2/ 
FiO2 ratio after the drug between cases and controls (p = 
0.21). Table 2 denotes the comparison of the means pre 
and post intervention by case control groups. Inhaled 
PGE1 was followed by an improvement in diastolic dys- 
function (grade I, p = 0.001) with a resulting improve- 
ment in LVEDP (12 ± 2, p = 0.001) as well as Pa pres- 
sures (97.09 ± 30.06, p = 0.04) and a non significant im- 
provement in PaO2/ FiO2 ratio (161.45 ± 77.52, p = 0.21) 
as shown in Figures 2 and 3 and Table 3. There were no 
patients who had to be removed from the trial for hemo- 
dynamic instability or worsening hypoxia. There were 
also no other complications observed.  




In our study we found that PGE1 when nebulised in such 
critically ill patients is safe and effective in decreasing 
the diastolic dysfunction, left ventricular end diastolic 
pressures, and pulmonary artery pressures which contri- 
butes significantly to the morbidity and mortality of 
Figure 2. Comparison of P/F ratio in cases and controls be- 
ore and after drug. f   
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Table 2. Comparison between the two groups post intervention (Data are means % and 95% CI). 
Endpoint PGE 1 (n = 34) Placebo (n = 33) p value 
Mean diastolic dysfunction Grade I Grade I 0.001 
LVEDP    
<10 19.2 (8.62 - 38.08) 27.6 (14.73 - 45.88) 0.001 
10 - 15 57.5 (38.79 - 74.52) 48.3 (31.29 - 65.67)  
>15 23.1 (11.11 - 42.25) 24.1 (12.27 - 42.28)  
Pa pressure 82.66 (75.12 - 90.2) 97.09 (86.67 - 107.51) 0.04 
PaO2/FiO2 161.45 (134.59 - 188.31) 186.80 (162.87 - 210.73) 0.21 
 
Table 3. Comparison between pre- and post-nebulisation parameters (Data are means % and 95% CI). 
Characteristics PGE1 group (n = 34) Placebo group ( n = 33) p value 
PaO2FiO2 baseline, Mean (SD) 148.38 ± 60.05 162.84 ± 66.20 0.52 
PaO2FiO2 after drug, Mean (SD) 161.45 ± 77.52 186.80 ± 69.07  
Pa pressure baseline, Mean (SD) 81.35 ± 16.91 80.38 ± 26.86 0.12 
Pa pressure after drug, Mean (SD) 82.66 ± 21.77 97.09 ± 30.06  
LVEDP baseline 18.27 ± 3.45 17.83 ± 3.79 0.36 
LVEDP after drug 14.12 ± 3.73 12.90 ± 3.24  
 
 
Figure 3. Comparison of PA pressures in cases and controls 
at baseline and after drug. 
 
such patients. We, however, could not demonstrate sig- 
nificance in the change in PaO2/FiO2 ratio or hypoxia, 
even though there was a rising trend in this post drug ad- 
ministration. These findings are of clinical relevance be- 
cause ARDS is a common cause of hypoxia, poor lung 
compliance and pulmonary hypertension in the ICU, all 
leading to multi organ failure, and in conjunction with 
sepsis (which usually is a precursor of ARDS) [18,19] is 
associated with high morbidity and mortality rates [20]. 
The acute respiratory distress syndrome (ARDS) is char- 
acterized by a ventilation-perfusion mismatch resulting 
from the non-ventilated atelectatic lung areas which re- 
sults in a intrapulmonary right-to-left shunt with the con- 
sequence of severe arterial hypoxemia. The application 
of inhaled PGE1 is a therapeutic option to selectively in- 
fluence pulmonary blood flow in order to improve arte- 
rial oxygenation and to decrease pulmonary artery pres- 
sure without relevant systemic side effects. Although there 
are case reports present in literature, no randomized con- 
trolled trials have been carried out to our knowledge to 
demonstrate a benefit in patient populations covering the 
entire severity range of acute lung injury and diastolic 
dysfunction parameters. Small studies have shown an im- 
provement in RV function in ARDS with inhaled nitric 
oxide (iNO) [21,22]. We therefore suggest that based on 
our results PGE1 represents a feasible rescue treatment 
for ARDS patients with diastolic dysfunction, raised 
LVEDP and increased pulmonary artery pressures and is, 
therefore, an important option for diastolic heart failure 
occurring in the presence of ARDS until further larger 
trials are carried out and other alternative treatments are 
observed. Studies looking at inhaled nitric oxide (iNO) 
suggest a large cost involved as well as use only in spe- 
cialized centers and therefore may not be a realistic op- 
tion for our population [23,24]. 
This is the first time such a study has been conducted 
and it showed robustly the efficacy of the drug as well as 
generalisability of effect, albeit for a short term.  
The small cohort due to decreased rates of ARDS after 
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commencement of the study in our ICU could be taken as 
a potential limitation. The study could enroll fewer than 
expected patients due to the drop in the incidence of 
ARDS in our ICU during the course of the study. One 
can speculate as to the causes of this, one being better 
ventilatory management of the disease or better control 
of severe sepsis due to the Surviving sepsis campaign 
[18]. 
Also, we were not observing the survival or length of 
stay in the ICU of these patients which is also a potential 
limitation of the study. Based on the available observa- 
tions, we found that inhaled PGE1 in patients with 
ARDS safe and effective in reducing pulmonary artery 
pressures. However, results of improvement in hypoxia, 
although promising was non significant. We would ad- 
vocate larger multi center trials to look at the effect on 
hypoxia as well as patient centered end points such as 
survival and length of stay outcomes, as well as ventila- 
tory requirements. 
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